This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about 60S ribosomal protein L23.
Human | |
---|---|
Gene Name: | RPL23 |
Uniprot: | P62829 |
Entrez: | 9349 |
Belongs to: |
---|
universal ribosomal protein uL14 family |
MGC111167; MGC117346; MGC72008,60S ribosomal protein L17,60S ribosomal protein L23; ribosomal protein L17; ribosomal protein L23; rpL17
Mass (kDA):
14.865 kDA
Human | |
---|---|
Location: | 17q12 |
Sequence: | 17; NC_000017.11 (38847860..38853721, complement) |
The Anti-RPL23 Marker is used for Molecular Targeting and Clinical Applications. Learn more about this antibody by reading the following! We'll discuss the properties and the many uses it can have in your research. This article is meant to give you a brief overview of these uses and how Boster Bio changes the face molecular target science. Here are some examples.
The Anti-RPL23 Marker in Bostro Bio is a human monoclonal antibody that reacts with ribosomal protein L23. The protein is an organelle that catalyzes protein synthesis, called ribosomes. There are four RNA types and 80 structurally distinct protein species in ribosomes. The RPL23 antibody recognizes the protein and reacts to the appropriate target cells in WB tests.
The RPL23 marker protein is a Pre-60S subunit. This marker protein is expressed in pre-60S nuclei. RRS1 knockdown inhibits nuclear export RPL11. This hinders cMyc transcription. Knockdown of RRS1 also stops ribosome formation in the nucleus. It also impacts nuclear export and ribosome metabolism.
The RPL23 marker also inhibits c–Myc activity. This protein is located in the nucleus, and is recruited by Syo1. This RNA marker inhibits c-Myc activity by binding to miR-24. It also inhibits transcription. RPL11 & RPL23 work together to suppress the c-Myc.
RNAi inhibition in BT549 cells and RPL11 knockdown decrease invasion and metastaticis. The invasion and metastasis of human breast cancer cells are controlled by the RPL11-cMyc-SNAIL axis. Boster Bio's anti RPL23 Marker is an important therapeutic target. RPL11 is a key component of breast cancer. However, more research is needed.
The survival of cells is dependent upon the RPL23 protein. Knockdown of RPL23 expression induces pro-apoptosis and increases the production of cleaved caspase-3. This marker can easily be detected by Western Blotting. The clinical applications of the RPL23 marker in cancer have been established. We present a summary of the research and some clinical information. Experiments with cancer cell lines have shown that the RPL23 gene is a valid cancer marker.
A study from a university in the United States has shown that RPL23 expression is associated with poor outcomes in patients with hepatocellular carcinoma (HCC). Researchers found that HCC cells that express high levels of RPL23 displayed poor prognosis. Depleting RPL23 also inhibited HCC cells' proliferation, invasion, distant metastasis, and invasion. RPL23 could therefore be a valuable tool in the treatment of HCC.
Inversely, the RPL23 gene expression correlates with the percentage of apoptotic cell in patients with MDS at higher risk. RPL23 gene transcription is also associated to the disease's progress. This is especially useful in the early stages, when patients have low-quality blood. A high RPL23 can indicate the onset and progression of malignancy.
The RPL23 gene is not only used in clinical practice, but also has potential roles in the immune systems. It has been suggested that it may play a role on the Miz1/c–Myc pathway. This pathway is thought to increase Myc-dependent, oncogenic functions. In addition to this, elevated RPL23 expression increases c-Myc function. It also suppresses Cdk inhibitors in the Miz-1 mediated pathway.
RPL23 has been implicated in the development of many cancers, including MDS and AML. Although it has been implicated with the evolution of aML/MDS, cellular senescence could be a subordinate characteristic of RPL23 gene overexpression. It also inhibits HDM2 Ubiquitin Ligase, which activates the p53. This gene is associated with anti-tumour effects and growth inhibitory effects on gastric cancer cells.
RPL23 was identified as a low-risk marker during a study that involved a group of MDS patient. It is a sensitive test that can be used to screen MDS patients. It is a reliable predictor of disease risk. It has many potential uses in treating MDS and predicting other cancers. This marker has been shown to be highly sensitive and accurate in predicting the risk of relapse. It is also a good predictor of survival.
Researchers can access the Boster Bio Molecular targeting with the RPL23 marker for their research. This antibody binds specifically to ribosomal Protein L23. This protein is found within the cells' chloroplast. The antibody can be used for IHC and ELISA. This antibody has been tested on a variety of species, including Human, Mouse, and Monkey.
PMID: 1861993 by Herault Y., et al. cDNA and predicted amino acid sequences of the human ribosomal protein genes rpS12 and rpL17.
PMID: 1874450 by Berchtold M.W., et al. Isolation and analysis of a human cDNA highly homologous to the yeast gene encoding L17A ribosomal protein.